|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liraglutide, a long-acting human glucagon-like peptide-a analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemica in patients with type 2 diabetes显示文摘 | VILSBLL T ZDRAVKOVIC M LE-THI T | 2007 | Diabetes Care2007，30，6： | 1 |
| 2 | Liraglutide, a once- daily human GLP-1 analogue,improves pancreatic B-cell function and arginine-slimulated insulin in patients with Type 2 diabetes secretion during hyperglycaemia mellitas显示文摘 | VILSBLL T BROCK B PERRILD H | 2008 | Diabet Med2008，25，2： | 1 |
| 3 | Liraglutide treatment,blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study显示文摘 | VILSBLL T ZDRAVKOVIC M LE-THI T | 2006 | Diabetes2006，55，1： | 1 |
| 4 | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes 显示文摘 | Courreges JP Vilsbll T Zdravkovic M | 2008 | Diabete Med2008，25，： | 1 |
| 5 | Liraglutide,a long-acting human glucagon-like peptide analog,given as mono-therapy significantly improves glycemic control and lowers body weight without risk of hypoglycemica in patients with type 2 diabetes显示文摘 | Vilsbll T Zdravkovic M Le-thi T | 2007 | Diabetes Care2007，30，6： | 1 |
| 6 | Liraglutide treatment, blood presser and biomarkers of cardiovascu- lar risk in patients with type 2 diabetes: 14 week mono- therapy study 显示文摘 | Vilsbll T Zdaravkovic M Le-Thi T | 2006 | Diabetes2006，55，1： | 1 |
| 7 | The effects of glucagon-like peptide-I on the beta cell 显示文摘 | Vilsbll T | 2009 | Diabetes Obes Metab2009，11，3： | 1 |
| 8 | Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity 显示文摘 | Knop FK Aaboe K Vilsbll T | 2012 | Diabe- tes Obes Metab2012，14，6： | 1 |
| 9 | Glucagon-like peptide-1, glucose homeostasis and diabetes显示文摘 | Holst JJ Deacon CF Vilsbll T | 2008 | Trends Mol Med2008，14，： | 1 |
| 10 | Twelve weeks treatment with the DPP -4 inhibitor, sitagliptin, prevents degradation of peptide YY and improve glucose and non - glucose induced insulin secretion in patients with type 2 diabetes mellitus 显示文摘 | Aaboe K Knop FK Vilsbll T | 2010 | Diabetes Obes Metab2010，12，4： | 1 |
| 11 | Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy sig- nificantly improves glyeemie control and lowers body weight without risk of hypoglycemia in patients with type 2 dibetes 显示文摘 | Vilsbll T Zdravkovic M Le-Thi T | 2007 | Diabetes Care2007，30，6： | 1 |
| 12 | Twelve weeks treatment with the DPP-4inhibitor,sitagliptin,prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2diabetes mellitus显示文摘 | Aaboe K Knop FK Vilsbll T | 2010 | Diabe Ob M2010，12，4： | 1 |
| 13 | Efficacy and safety of sitagliptinwhen added to insulin therapy in patients with type 2 diabetes显示文摘 | Vilsbll T Rosenstoek J Yki-Jiirvinen H | 2010 | Diabetes Obes Metab2010，12，： | 1 |
| 14 | Efficacy and safe- ty of sitagliptin when added to insulin therapy in patients with type 2 diabetes显示文摘 | Vilsbll T Rosenstock J Yki-J~lrvinen H | 2010 | Diabetes Obes Metab2010，12，2： | 1 |
| 15 | Liraglutide significantly improves glycemic control and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes (abstract 115-OR)显示文摘 | Vilsbll T Zdravkovic M Le-Thi T | | 0，，1： | 1 |
| 16 | The incretin system and its role in type 2 diabetes mellitus 显示文摘 | Holst JJ Vilsbll T Deacon CF | 2009 | Mol Cell Endocrinol2009，297，12： | 1 |
| 17 | Lragutde significantly improves glycemic control and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes (abstract 115-0R) 显示文摘 | Vilsbll T Zdravkovic M Le-Thi T e ta | 2006 | Diabetes2006，55，： | 1 |
| 18 | Liraglutide,a long-acting human glucagon-like peptide-l, analog,given as monotherapysigniffcantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes显示文摘 | Vilsbll T Zdravkovic M Le Thi T | 2007 | Diabetes Care2007，50，： | 1 |
| 19 | Effects of glucagon-hke peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials 显示文摘 | Vilsbll T Christensen M Junker AE | 2012 | BMJ2012，344，： | 1 |
| 20 | Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improve glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus 显示文摘 | Aaboe K Knop FK Vilsbll T | 2010 | Diabetes Obes Metab2010，12，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员